Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06391489 · ClinicalTrials.gov registry record · NA

HOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS)

A NA study of Cognitive Dysfunction and Memory Impairment, sponsored by Dartmouth-Hitchcock Medical Center.

Active
Registry status
NA
Development phase
10
Enrollment target
1
Study location

NCT06391489: Active NA study of Cognitive Dysfunction and Memory Impairment, sponsored by Dartmouth-Hitchcock Medical Center.

NCT06391489 is a NA study of Cognitive Dysfunction and Memory Impairment that is active but no longer recruiting, run by Dartmouth-Hitchcock Medical Center. The registered enrollment target is 10 participants, below the 1,993-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (99% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06391489, a NA study of Cognitive Dysfunction and Memory Impairment, is active but no longer recruiting, sponsored by Dartmouth-Hitchcock Medical Center.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
10 participants
Enrollment target
1
Study location

Study Summary

The goal of this pilot study is to assess the feasibility of adapting and delivering the existing home-based epilepsy self-management intervention, HOBSCOTCH, for people with Post Acute Covid Syndrome (PACS). The main questions it aims to answer are: Can the current HOBSCOTCH program be adapted for people with PACS? Will people with PACS experience improved quality of life similar to that found in people with epilepsy after participating in the HOBSCOTCH program? Participants will be asked to: * attend nine, one-hour virtual (online and/or by telephone) HOBSCOTCH-PACS sessions with a one-on-one certified HOBSCOTCH-PACS coach * complete a brief clinical questionnaire about their diagnosis of PACS * complete seven questionnaires before and after the HOBSCOTCH-PACS sessions about their quality of life, memory and thinking processes (objective and subjective cognition), about their physical and mental health and about autonomic symptoms associated with their diagnosis of PACS * keep a short daily diary (using a smart phone app or on paper) about their PACS symptoms and use of the self-management strategies taught in the HOBSCOTCH-PACS program * complete two brief surveys to assess satisfaction with their experience after the entire HOBSCOTCH-PACS program

Primary Outcome

PROMIS Global-10 is a validated 10-question survey and part of the Patient-Reported Outcomes Measurement Information System (PROMIS) used to assess health care-related quality of life. Measures include overall health, pain, fatigue, social health, mental health, and physical health. 9 of the items are scored on a Likert Scale of 1 - 5 with 5 representing the best health care-related quality of life; higher scores are associated with better quality of life. One item related to pain is measured on

Interventions

  • BEHAVIORAL HOBSCOTCH-PACS

Study Locations (1)

New Hampshire

  • Dartmouth-Hitchcock - Lebanon

Trial Details

FieldValue
Enrollment Target 10 participants
Start Date 2024-05-14
Est. Completion 2026-12
Phase NA
Dartmouth-Hitchcock Medical Center

427 total trials

What the registry record for NCT06391489 still lists

NCT06391489 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 1,993-participant average among 45 other Cognitive Dysfunction trials with a reported enrollment target (99% lower).

The record links to 4 conditions, with Cognitive Dysfunction appearing as the primary indexed condition, and to 1 intervention - of which HOBSCOTCH-PACS is the first listed.

NCT06391489 reports a single indexed study location in New Hampshire.

Frequently Asked Questions

What is clinical trial NCT06391489 about?

NCT06391489 is a clinical study titled "HOBSCOTCH for People With Post Acute COVID-19 Syndrome (PACS)". The goal of this pilot study is to assess the feasibility of adapting and delivering the existing home-based epilepsy self-management intervention, HOBSCOTCH, for people with Post Acute Covid Syndrome (PACS). The main questions it aims to answer are: Can the current HOBSCOTCH program be adapted fo...

What is the current status of trial NCT06391489?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 10 participants. The study started on 2024-05-14. Estimated completion is 2026-12.

What conditions does trial NCT06391489 study?

This clinical trial studies the following conditions: Cognitive Dysfunction, Memory Impairment, Post-Acute COVID-19 Syndrome, Memory Dysfunction.

What interventions are being tested in trial NCT06391489?

The interventions under investigation include: HOBSCOTCH-PACS (BEHAVIORAL).

Who is sponsoring clinical trial NCT06391489?

This trial is sponsored by Dartmouth-Hitchcock Medical Center, which has 427 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06391489 being conducted?

This trial has 1 study location across New Hampshire. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cognitive Dysfunction

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06391489's enrollment target sits among peer trials

10 45th of 45 the lowest of 45 other Cognitive Dysfunction trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cognitive Dysfunction trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00623389 · 10 participants · NA

    Evaluation of an Advanced Lower Extremity Neuroprostheses

  • NCT01241864 · 10 participants · Phase 2

    Islet Transplantation in Type 1 Diabetic Kidney Allograft

  • NCT01293214 · 10 participants · NA

    Vascularized Composite Allotransplantation for Multiple Extremity Amputations

  • NCT01474148 · 10 participants · NA

    A Neuroprosthesis for Seated Posture and Balance

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06391489, the US trial registry maintained by the National Library of Medicine. NCT06391489 (small enrollment · single site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.